News Relief Therapeutics Holding SA OTC Markets

Equities

RLFTY

US7595JP3044

Delayed OTC Markets Other stock markets 09:35:45 2024-07-02 am EDT			5-day change	1st Jan Change
1.295 ^USD	-4.78%		-4.78%	-38.33%

Jun. 03	Relief Therapeutics Holding Announces Term Expiration of Michelle Lock as Interim Chief Executive Officer	CI
Jun. 03	Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting	Jun. 28	AQ
Relief Therapeutics Holding Announces Term Expiration of Michelle Lock as Interim Chief Executive Officer	Jun. 03	CI
Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors	Jun. 03	CI
Relief Therapeutics Restructures Management Team, Creates New Roles	May. 08	MT
Relief Therapeutics Announces Executive Changes	May. 08	CI
Relief Therapeutics Holding SA Announces Chief Financial Officer Changes	May. 08	CI
Relief Therapeutics Holding SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Relief Therapeutics' FY23 Loss Widens; Revenue Edges Down	Apr. 30	MT
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting	Mar. 28	AQ
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22	MT
Sector Update: Health Care	Mar. 22	MT
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	Mar. 22	MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	Mar. 22	MT
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE	Mar. 22	CI
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria	Mar. 22	AQ
Relief Therapeutics Extends CHF50 Million Share Subscription Facility with Largest Shareholder	Feb. 28	MT
Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor	Feb. 27	CI
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth	Dec. 06	AQ
Relief Therapeutics to Run Commercial Operations Via Partnership Model	Dec. 05	MT
Relief Therapeutics Announces CEO Transition	Nov. 23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Relief Therapeutics Holding SA OTC Markets

Equities

RLFTY

US7595JP3044

Summary

Filters